Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients

Table 4 Univariate and multivariate analyses of potential risk factors of tumor recurrence

Risk factors1	Univariate analysis			Multivariate analysis
	Hazard ratio	95%CI	P value(Cox’s regression)	Hazard ratio	95%CI	P value(Cox’s regression)
Sex, male/female	1.159	1.934-1.402	0.118
Age, > 50/ ≤ 50 yr	1.003	0.961-1.012	0.751
Platelet count, > 100/ ≤ 100 × 109/L	1.258	0.939-1.626	0.095
Hemoglobin, > 10/ ≤ 10 g/L	1.119	0.867-1.411	0.089
Serum AFP, > 400/ ≤ 400 ng/mL	0.960	0.929-1.011	0.079
HBV infection, yes/no	0.931	0.593-1.449	0.769
HBV DNA, > 1/ ≤ 1 × 105 copy/mL	1.323	0.912-1.883	0.119
AST, > 42/ ≤ 42 IU/L	1.171	0.933-1.425	0.127
Serum albumin, > 38/ ≤ 38 g/L	1.264	0.961-1.665	0.095
Serum total bilirubin, > 21/ ≤ 21 mmol/L	0.965	0.923-1.010	0.075
Prothrombin time, > 12.8/ ≤ 12.8 s	1.162	0.931-1.324	0.126
ICG retention at 15 min, > 10%/ ≤ 10%	1.349	0.903-1.989	0.115
Child-Pugh grade, A/B	1.011	0.914-1.097	0.779
Tumor size, > 50/ ≤ 50 mm	0.957	0.904-1.014	0.075
HBsAg, positive/negative	1.241	0.948-1.649	0.094
HBeAg, positive/negative	1.174	0.938-1.422	0.121
Type of resection, minor/major	1.131	0.949-1.381	0.086
Tumor number, < 3/≥ 3	2.050	1.051-3.549	0.034	1.324	1.035-1.776	0.045
Macrovascular invasion, yes/no	1.242	1.061-1.501	0.035
Hilar lymph nodes metastasis, yes/no	1.058	1.006-1.111	0.043
Sorafenib, yes/no	1.012	1.003-1.099	0.034a	1.353	1.012-1.763	0.039

¹The number of patients forin each risk factor analyzed = 102.